Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
NCT06503237
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
DRUG:
Anti-CD19 CART cells will be given IV at split doses.
Sponsor
The First Affiliated Hospital of University of Science and Technology of China